LONDON – 7 October 2026 — CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, today announces it has initiated dosing and fully enrolled the first cohort in its Phase I/II clinical trial of CHM-029 in patients with AML. This is the first example of a molecule designed using a protein-ligand co-folding model to progress into clinical studies.